Lexaria Bioscience Corp. (LEXX)
SEC fundamentals · as filed in 10-Q FY2026, period ended May 31, 2026 · updated Oct 22, 2026
as filed in 10-Q FY2026, period ended May 31, 2026 · View filings on EDGAR ↗
In its 10-Q for the period ended May 31, 2026, Lexaria Bioscience Corp. reported revenue of $0, net income of -$2.0M, and total assets of $4.8M. Every figure below is taken directly from Lexaria Bioscience Corp.'s SEC filings: each links to the source document on EDGAR.
Revenue trend
Revenue · FY2016–FY2025 · as reported
- FY2016 revenue
- $40,718
- FY2025 revenue
- $705,923
Revenue and net income by fiscal year
As reported in each year’s annual filing · USD
| Fiscal year | Revenue | Net income |
|---|---|---|
| FY2025 | $705,923 | -$11.9M |
| FY2024 | $464,278 | -$5.8M |
| FY2023 | $226,208 | -$6.7M |
| FY2022 | $255,397 | -$7.3M |
| FY2021 | $722,738 | -$4.0M |
| FY2020 | $384,543 | -$4.1M |
| FY2019 | $222,610 | -$4.2M |
| FY2018 | $433,287 | -$6.6M |
| FY2017 | $63,639 | -$1.9M |
| FY2016 | $40,718 | -$1.3M |
Recent SEC filings
Filed by the registrant · newest first · insider forms and holder schedules not included
| Form | Filed | Source |
|---|---|---|
| 8-K | Sep 9, 2026 | on EDGAR ↗ |
| 8-K | Sep 1, 2026 | on EDGAR ↗ |
| 8-K | Aug 17, 2026 | on EDGAR ↗ |
| 8-K | Aug 10, 2026 | on EDGAR ↗ |
| 8-K | Jul 30, 2026 | on EDGAR ↗ |
| 10-Q | Jul 13, 2026 | on EDGAR ↗ |
| 10-Q | Apr 13, 2026 | on EDGAR ↗ |
| 8-K | Feb 6, 2026 | on EDGAR ↗ |
| 8-K | Jan 28, 2026 | on EDGAR ↗ |
| 10-Q | Jan 13, 2026 | on EDGAR ↗ |
Balance Sheet
as of May 31, 2026 · 10-Q
Income Statement
10-Q (quarterly) · period ended May 31, 2026
Per Share & Cash Flow
10-Q (quarterly) · period ended May 31, 2026
| EPS (diluted) | $-0.08 | Earnings | source ↗ |
| EPS (basic) | — | — | source ↗ |
| Shares Outstanding | 24.8M | Entity | source ↗ |
| Cash from Operations | -$1.6M | Net | source ↗ |
| Cash from Financing | $0 | Net | source ↗ |
| Cash from Investing | -$27,089 | Net | source ↗ |
Restatement history
Point-in-time19 of 370 annual fact-keys were materially restated between filings: what Lexaria Bioscience Corp. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.
See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.
Deeper fundamentals
A free API key reaches LEXX’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.
Programmatic access
Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.
- These fundamentals, as filed
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/LEXX
MCP tool:
get_sec_fundamentals ticker=LEXX - The same figures as they were known on any past date
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/LEXX/as-of/YYYY-MM-DD
MCP tool:
get_asof_fundamentals ticker=LEXX as_of=YYYY-MM-DD - Fiscal-year trajectory: revenue, margins, free cash flow
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/LEXX/history
MCP tool:
get_fundamentals_history ticker=LEXX - Leverage, liquidity, margin and return ratios
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/financial-health/LEXX
MCP tool:
get_financial_health ticker=LEXX
Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.